Patents by Inventor Jane A. Gross

Jane A. Gross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO HUMAN TUMOR NECROSIS FACTOR RECEPTOR
    Publication number: 20100197895
    Abstract: Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.
    Type: Application
    Filed: May 29, 2009
    Publication date: August 5, 2010
    Inventors: Jane A. Gross, Wenfeng Xu, Randal M. Henne, Francis J. Grant
  • TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20100183609
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: October 26, 2009
    Publication date: July 22, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Murine zcytor17 ligand polypeptides
    Patent number: 7740834
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: June 22, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E Kuestner
  • TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20100130728
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 27, 2010
    Applicant: ZYMOGENETICS, INC.
    Inventors: MARK W. RIXON, JANE A. GROSS
  • TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20100129384
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: November 5, 2009
    Publication date: May 27, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists
    Patent number: 7723048
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: May 25, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine Bilsborough, Jane A. Gross
  • CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
    Publication number: 20100055101
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: August 21, 2009
    Publication date: March 4, 2010
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS
    Publication number: 20090325196
    Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease.
    Type: Application
    Filed: April 24, 2009
    Publication date: December 31, 2009
    Applicants: ZymoGenetics, Inc., University of Washington
    Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
  • Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same
    Patent number: 7635767
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: December 22, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Cytokine zalpha11 ligand antibodies
    Patent number: 7626002
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: December 1, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS
    Publication number: 20090280121
    Abstract: The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Application
    Filed: July 2, 2009
    Publication date: November 12, 2009
    Inventors: Donald Y.M. Leung, Janine Bilsborough, Jane A. Gross
  • CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
    Publication number: 20090274694
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: June 12, 2009
    Publication date: November 5, 2009
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Methods of using cytokine zalpha11 ligand
    Patent number: 7611699
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: November 3, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Human tumor necrosis factor receptor
    Patent number: 7608686
    Abstract: Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: October 27, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Jane A. Gross, Wenfeng Xu, Randal M. Henne, Francis J. Grant
  • Cytokine zalpha11 ligand fusion proteins
    Patent number: 7592425
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: September 22, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Cytokine zalpha11 ligand fusion proteins
    Patent number: 7579441
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: August 25, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20090209006
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: January 26, 2009
    Publication date: August 20, 2009
    Applicant: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Cytokine zalpha11 ligand fusion proteins
    Patent number: 7572892
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: August 11, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Cytokine zalpha11 ligand fusion proteins
    Patent number: 7569670
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: August 4, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Cytokine zalpha11 ligand polynucleotides
    Patent number: RE41129
    Abstract: The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: February 16, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond